Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb;89(2):276-82.
doi: 10.1038/clpt.2010.307. Epub 2010 Dec 22.

A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction

G P Galloway  1 , R Buscemi, J R Coyle, K Flower, J D Siegrist, L A Fiske, M J Baggott, L Li, D Polcin, C Y A Chen, J Mendelson
Affiliations
Randomized Controlled Trial

A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction

G P Galloway et al. Clin Pharmacol Ther. 2011 Feb.

Abstract

Sixty treatment-seeking individuals with methamphetamine (MA) dependence entered a randomized, placebo-controlled, double-blind clinical trial of oral dextroamphetamine (d-AMP) as a replacement therapy for MA dependence. The subjects took 60 mg sustained-release d-AMP for 8 weeks, during which time they received eight 50-min sessions of individual psychotherapy. Adverse events and urine toxicology for MA were assessed two times a week. There were no serious adverse events. Urine samples containing <1,000 ng/ml of MA were classified as negative for MA. The MA-negative scores in the d-AMP group (3.1 ± SD 4.6) were no higher than those in the placebo group (3.3 ± SD 5.3; P > 0.05). However, withdrawal and craving scores were significantly lower in the d-AMP group (P < 0.05 for both). Although subjects taking d-AMP did not reduce their use of MA, the significant reductions observed in withdrawal and craving scores in this group support the need for further exploration of d-AMP as a pharmacologic intervention for MA dependence, possibly at higher doses.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declared no conflict of interest.

Figures

Figure 1
Figure 1
Subject flow diagram.
Figure 2
Figure 2
Adverse events by group. d-AMP, dextroamphetamine.
Figure 3
Figure 3
Proportions of methamphetamine-negative urine samples by time and group. d-AMP, dextroamphetamine.
Figure 4
Figure 4
Amphetamine Withdrawal Questionnaire scores by time and group. d-AMP, dextroamphetamine.
Figure 5
Figure 5
Methamphetamine craving visual analog scale scores by time and group. d-AMP, dextroamphetamine.
See this image and copyright information in PMC

References

    1. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health. [12 January 2009];2006 < http://www.oas.samhsa.gov/methTabs.htm>. - PubMed
    1. Leamon MH, Flower K, Salo RE, Nordahl TE, Kranzler HR, Galloway GP. Methamphetamine and paranoia: the methamphetamine experience questionnaire. Am. J. Addict. 2010;19:155–168. - PMC - PubMed
    1. Johanson CE, et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl.) 2006;185:327–338. - PubMed
    1. Salo R, et al. Cognitive control and white matter callosal microstructure in methamphetamine-dependent subjects: a diffusion tensor imaging study. Biol. Psychiatry. 2009;65:122–128. - PMC - PubMed
    1. Nicosia N, et al. The Economic Cost of Methamphetamine Use in the United States. Santa Monica, CA: RAND Corp.; 2005. 2005.

Publication types